fluoxetine + phosphocreatine

Fluoxetine + phosphocreatine is an investigational combination therapy consisting of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the cellular energy supplement phosphocreatine. This combination has been studied as an augmentation strategy for major depressive disorder (MDD), with the aim of achieving a more rapid antidepressant effect than fluoxetine alone. Fluoxetine increases synaptic serotonin levels by inhibiting its reuptake, while phosphocreatine serves as a high-energy phosphate donor that supports cellular bioenergetics, potentially addressing metabolic deficits observed in depression. The combination is administered as oral fluoxetine and intravenous phosphocreatine during initial treatment phases[1][2].